Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Blood (2023) 142 (Supplement 1): 4962.

https://doi.org/10.1182/blood-2023-174479

Published: 2023

Journal Articles

Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2023) 142 (Supplement 1): 4988.

https://doi.org/10.1182/blood-2023-181031

Published: 2023

Journal Articles

Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide

Samer A. Srour, Amandeep Salhotra, Robert Lowsky, Rasmus T. Hoeg, Edmund K. Waller, Anna Pavlova, J. Scott McClellan, Nathaniel B. Fernhoff, Everett H. Meyer, Mehrdad Abedi

Blood (2023) 142 (Supplement 1): 773.

https://doi.org/10.1182/blood-2023-189534

Published: 2023

Journal Articles

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Qaiser Bashir, Marina Y. Konopleva, Glorette Abueg, Jeremy Ramdial, Chitra Hosing, Samer A. Srour, Amin Alousi, Uday R. Popat, Yago Nieto, Gheath Alatrash, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Naveen Pemmaraju

Blood (2023) 142 (Supplement 1): 7058.

https://doi.org/10.1182/blood-2023-178874

Published: 2023

Journal Articles

Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2023-173040

Published: 2023

Journal Articles

Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

Blood (2023) 142 (Supplement 1): 233.

https://doi.org/10.1182/blood-2023-181880

Published: 2023

Journal Articles

Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 4920.

https://doi.org/10.1182/blood-2023-185025

Published: 2023

Journal Articles

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4972.

https://doi.org/10.1182/blood-2023-189844

Published: 2023

Journal Articles

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2023-174558

Published: 2023

Journal Articles

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Caspian H. Oliai, Jeremy M. Pantin, Rasmus T. Hoeg, Lori S. Muffly, Sagar S. Patel, Arpita Gandhi, Robert Lowsky, Amandeep Salhotra, Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, Anna Pavlova, Nathaniel B. Fernhoff, Irene Agodoa, J. Scott McClellan, Mehrdad Abedi, Robert S. Negrin, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 230.

https://doi.org/10.1182/blood-2023-186749

Published: 2023

Journal Articles

Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience

Blood (2023) 142 (Supplement 1): 4963.

https://doi.org/10.1182/blood-2023-173697

Published: 2023

Journal Articles

Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results

Blood (2023) 142 (Supplement 1): 774.

https://doi.org/10.1182/blood-2023-172980

Published: 2023

Journal Articles

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS): A Review of Pharmacovigilance

Ugochi Ebinama, Rishab Prakash, Paolo Strati, Sairah Ahmed, Sherry Adkins, Samer A. Srour, Michael L. Wang, Preetesh Jain, Elizabeth J. Shpall, Anath Lionel, Meng Lui, Sattva S. Neelapu, Krina K. Patel, Swami P. Iyer

Blood (2023) 142 (Supplement 1): 5132.

https://doi.org/10.1182/blood-2023-185190

Published: 2023

Journal Articles

Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis

Alejandro Marinos Velarde, Rima M. Saliba, Celina Ledesma, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Uday R. Popat, Qaiser Bashir, Yago Nieto, David Marin, Betul Oran, Amanda L. Olson, Samer A. Srour, Amin Alousi, Jeremy Ramdial, Partow Kebriaei, Alessandra Ferrajoli, William G. Wierda, Richard E. Champlin, Chitra Hosing

Blood (2023) 142 (Supplement 1): 7086.

https://doi.org/10.1182/blood-2023-173194

Published: 2023

Journal Articles

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 7070.

https://doi.org/10.1182/blood-2023-189109

Published: 2023

Journal Articles

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Blood (2022) 140 (Supplement 1): 654–656.

https://doi.org/10.1182/blood-2022-165654

Published: 2022

Journal Articles

High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

Blood (2022) 140 (Supplement 1): 1183–1184.

https://doi.org/10.1182/blood-2022-156121

Published: 2022

Journal Articles

Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.

Blood (2022) 140 (Supplement 1): 12005–12007.

https://doi.org/10.1182/blood-2022-170750

Published: 2022

Journal Articles

HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT

Rohtesh S. Mehta, Rima M. Saliba, Amin M. Alousi, Gheath Alatrash, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Betul Oran, Uday R. Popat, Muzaffar H. Qazilbash, Jeremy L. Ramdial, Gabriela Rondon, Samer A. Srour, Katy Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Kai Cao

Blood (2022) 140 (Supplement 1): 4880–4881.

https://doi.org/10.1182/blood-2022-158689

Published: 2022

Journal Articles

Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide

Amandeep Salhotra, Samer A Srour, Rasmus T Hoeg, Ayman Saad, Everett H Meyer, Anna Pavlova, Edmund K. Waller, Mwe Mwe Chao, J Scott McClellan, Nathaniel B Fernhoff, Robert Lowsky, Mehrdad Abedi

Blood (2022) 140 (Supplement 1): 1865–1866.

https://doi.org/10.1182/blood-2022-170459

Published: 2022

NARROW

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation

Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience

Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS): A Review of Pharmacovigilance

Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.

HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT

Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only